leadf
logo-loader
RNS
viewSensyne Health PLC

Sensyne Health PLC - Sensyne Health achieves 5 million patient target

RNS Number : 3984F
Sensyne Health PLC
16 November 2020
 

Sensyne Health achieves five million patient target

set at IPO

 

~ NHS equity ownership in Sensyne now 11.7% ~

~ Sensyne model shows benefit to NHS and UK patients ~

 

Oxford, U.K. 16 November 2020: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the UK Clinical AI company, today announces that, following its new non-exclusive Strategic Research Agreement ("SRA") with Somerset NHS Foundation Trust announced this morning, the Company has achieved a major objective set at its IPO in August 2018 of growing its anonymised patient database to five million patients.

 

The new SRA now brings the combined total of anonymised patient data available for analysis by Sensyne to 5.6 million patients.  The data enables the ethical application of clinical artificial intelligence research on anonymised patient data to improve patient care and accelerate research into new medicines. 

 

In line with the strategy laid out at the time of its IPO, with access now to anonymised data on more than five million patients, Sensyne is able to cover a broader range of research across different clinical areas, deliver powerful data insights to speed up the development of novel approaches to new medicines, and develop AI-powered clinical decision support tools to improve patient care.

 

NHS Benefit

The unique nature of Sensyne's business model, where NHS Trusts receive an equity stake in the Company, a royalty on revenues that are generated from research undertaken under the SRAs and an investment of up to £250,000 per year over the five-year term, means the NHS has benefitted from Sensyne's partnership approach in a variety of ways, with long-term benefits potentially to come.

 

Since August 2018, the NHS has already received a total financial return of £19,460,000 through its relationship with Sensyne, comprising:

·    £18,300,000 via equity ownership in Sensyne of 11.7% [1]

·    £160,000 in shared revenues

·    £1,000,000 in IT and technology infrastructure investment

 

Patient Benefit  

Research conducted by Sensyne using SRA data includes:

·    Stroke prediction - identifying additional risk factors to help clinicians better predict stroke and improve care.

·    Heart failure treatment - identifying specific subgroups of patients suffering from heart failure to help personalise treatments that are effective for particular patient groups.

·    COVID-19 lung impact - developing algorithms using computer vision for the analysis of images to detect COVID-19 related lung disease. 

· COVID-19 risk - developed algorithms to predict the risk of intensive care unit admission,  invasive mechanical ventilation and death in patients with COVID-19 infection. 

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

"Reaching this five million patient milestone with our NHS Trust partners is a great achievement and means that together we have created a world-class medical research capability here in the UK. Over the past two years we have demonstrated how Sensyne's clinical AI can be used to deliver better patient care and to accelerate medical research.  We have also shown how our unique partnership model not only delivers clinical benefits but also provides a significant financial return back into the NHS. 

"We are experiencing enthusiasm from other NHS Trusts across the UK interested in the Sensyne model and see the potential to grow our anonymised patient database beyond five million. We are also seeing interest in Sensyne's model beyond the UK, and especially in the US, as other healthcare systems begin to think about how to use their own patient data for medical research in a transparent and fair way."

-ENDS-

 

 

 

For more information please contact:

Sensyne Health (www.sensynehealth.com)

+44 (0) 330 058 1845

Lord (Paul) Drayson PhD FREng FMedSci, Chief Executive Officer

 

Michael Norris, Chief Financial Officer

 

Consilium Strategic Communications

+44 (0) 7780 600290

Mary-Jane Elliott

 

Sukaina Virji

 

Melissa Gardiner

 

CSCsensynehealth@consilium-comms.com

 

 

About Sensyne Health 

 

Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

 

For more information, please visit: www.sensynehealth.com

 

[1] As at the mid-price close on 13/11/20.   Excludes George Eliot & Wye Valley which remain subject to NHS England approval prior to final closing and issue of shares in Sensyne. Number assumes issuance of shares to Milton Keynes and Somerset Trusts.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAGRBDBGGBDGGL

Quick facts: Sensyne Health PLC

Price: -

Market: AIM
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

5 min read